Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?

類似資料

• SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer
  著者:: Tabbò, Fabrizio, 等
  出版事項: (2019)
• Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations
  著者:: Bironzo, Paolo, 等
  出版事項: (2021)
• Epidermal growth factor receptor tyrosine kinase inhibitors
  著者:: Ranson, M
  出版事項: (2004)
• Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
  著者:: Zhai, Haoran, 等
  出版事項: (2015)
• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
  著者:: Ohashi, Kadoaki, 等
  出版事項: (2013)